🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ StockGenie AI

Kopran Limited KOPRAN NSEPHARMA

Healthcare · Drug Manufacturers - General · India
https://www.kopran.com

Kopran Limited, an integrated pharmaceutical company, engages in the development, manufacture and marketing of active pharmaceutical ingredients and finished dosage forms in India and internationally. The company offers its products in various dosage forms, including tablets, capsules, syrups, dry powder, suspension, and injectables, as well as branded and generic formulations. It also provides drugs in the categories of macrolide, antibacterial, anticonvulsant, anti-hypertensive, anti- helminthics, anti-acne, anti-infective, anti-thrombotic, sterile carbapenem, urological, neuromodulator, antidiabetic, pain management, neuromodular, gastroenterology, and cardiovascular. In addition, the company offers drugs for erectile dysfunction, antiallergics, respiratory, oncology, central nervous system, antiprotozoal, anthelmintics, antipeptic ulcer and gut, and others. Kopran Limited was incorporated in 1958 and is based in Mumbai, India.

READ MORE ›
₹206.27
+14.10% 1Y

Market & Price

Market Cap
₹995.99 Cr
Current Price
₹206.27
High / Low (52W)
₹206.27 / ₹108.04
Beta
0.76

Valuation

Stock P/E
38.77
Industry PE
37.60
Forward P/E
36.38
PEG Ratio
-
Book Value
₹104.02
Price to Book
1.98
P/S
1.46
EV/EBITDA
14.64
Dividend Yield
1.45%

Profitability & Returns

ROCE
7.97%
ROE
4.91%
ROA
4.31%
Profit Margin
3.78%
Op Margin
15.41%
EPS (Latest Qtr)
₹3.91
EPS (TTM)
₹5.32

Balance Sheet & Liquidity

Debt/Equity
0.29
Quick Ratio
0.78
Current Ratio
1.51
Debt
₹152.69 Cr
Total Assets
₹908.36 Cr
Current Assets
₹523.18 Cr
Working Capital
₹177.00 Cr

Ownership

Promoter Holding
48.88%
Chg in Prom Hold
-
FII / Inst Holding
0.19%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
₹1,140.71 Cr
Total Revenue (TTM)
₹681.42 Cr
EBITDA
₹77.90 Cr
Free Cash Flow
₹5.68 Cr
Operating Cash Flow
₹66.75 Cr
Shares Outstanding
₹4.83 Cr
Gross Margin
35.57%
Payout Ratio
56.29%

Growth (CAGR)

Revenue 5Y
7.52%
Profit 5Y
-1.87%
Revenue (YoY)
35.80%
Earnings (YoY)
94.80%

PROS

  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Earnings shrank at -1.9% CAGR over 5 years.
  • RSI at 77 suggests overbought conditions.

* The pros and cons are auto-generated from financial metrics.

Price Chart

NSE TradingView Screener.in

Fundamental Growth

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 KOPRAN Kopran Limited NSEPHARMA 206.27 38.77 ₹995.99 Cr 1.45% 7.97% 4.91% 7.52% -1.87%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,799.20 37.59 ₹4.32 L Cr 0.92% 17.94% 14.72% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 6,667.00 68.97 ₹1.77 L Cr 0.45% 18.96% 16.19% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,410.80 68.96 ₹1.49 L Cr 0.86% 9.06% 16.98% 13.27% 20.21%
5 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,401.00 29.16 ₹1.13 L Cr 0.93% 14.88% 11.74% 7.23% 11.45%
6 DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA 1,303.50 25.90 ₹1.09 L Cr 0.61% 14.00% 11.83% 10.96% -2.35%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,077.70 21.51 ₹1.08 L Cr 0.09% 19.24% 18.32% 16.55% 36.99%
8 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,267.70 19.49 ₹1.04 L Cr 0.53% 28.42% 26.91% 19.10% 131.46%
9 MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA 2,375.60 51.29 ₹98,090.71 Cr 0.08% 13.78% 12.45% 17.73% 14.28%
⚙Ad space

Quarterly Results

Figures in INR.

Metric Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue -166.24 Cr172.36 Cr135.22 Cr117.91 Cr194.28 Cr234.02 Cr
Cost of Revenue -105.70 Cr115.36 Cr85.40 Cr76.01 Cr131.06 Cr146.54 Cr
Gross Profit -60.54 Cr57.00 Cr49.81 Cr41.90 Cr63.22 Cr87.47 Cr
Operating Expenses -41.62 Cr43.78 Cr39.94 Cr43.22 Cr47.41 Cr51.42 Cr
Operating Income -18.91 Cr13.22 Cr9.87 Cr-1.32 Cr15.82 Cr36.06 Cr
EBITDA -20.01 Cr20.35 Cr16.69 Cr-5.25 Cr17.83 Cr33.04 Cr
Interest Expense -2.16 Cr2.77 Cr2.54 Cr2.09 Cr2.67 Cr3.17 Cr
Pretax Income -13.86 Cr13.71 Cr9.89 Cr-11.63 Cr10.74 Cr25.35 Cr
Tax Provision -3.46 Cr4.03 Cr2.44 Cr-1.70 Cr1.40 Cr6.48 Cr
Net Income -10.40 Cr9.68 Cr7.45 Cr-9.92 Cr9.34 Cr18.87 Cr
Diluted EPS 1.532.152.001.54-2.061.933.91

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue -548.18 Cr610.09 Cr629.60 Cr681.42 Cr
Cost of Revenue -374.00 Cr416.21 Cr404.62 Cr439.02 Cr
Gross Profit -174.18 Cr193.88 Cr224.99 Cr242.41 Cr
Operating Expenses -128.89 Cr132.35 Cr167.68 Cr181.98 Cr
Operating Income -45.29 Cr61.53 Cr57.31 Cr60.43 Cr
EBITDA -53.28 Cr86.82 Cr76.88 Cr62.30 Cr
Interest Expense -4.50 Cr6.39 Cr9.34 Cr10.47 Cr
Pretax Income -36.07 Cr67.54 Cr51.95 Cr34.36 Cr
Tax Provision -8.83 Cr16.59 Cr13.40 Cr8.62 Cr
Net Income -27.23 Cr50.96 Cr38.55 Cr25.73 Cr
Diluted EPS 13.775.6510.577.99-

Compounded Sales Growth

5 Years:7.52%
1 Year:35.80%

Compounded Profit Growth

5 Years:-1.87%
1 Year:94.80%

Stock Price Performance

1 Year:+14.10%
6 Months:+58.49%
3 Months:+60.37%
1 Month:+25.29%

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets -649.70 Cr743.25 Cr844.01 Cr908.36 Cr
Current Assets -399.07 Cr454.03 Cr509.75 Cr523.18 Cr
Cash & Equivalents -7.40 Cr8.09 Cr19.47 Cr68.20 L
Inventory -130.61 Cr138.49 Cr169.42 Cr164.21 Cr
Receivables -162.56 Cr212.33 Cr214.93 Cr262.66 Cr
Total Liabilities -210.45 Cr252.00 Cr325.66 Cr378.08 Cr
Current Liabilities -176.97 Cr218.53 Cr288.97 Cr346.18 Cr
Long Term Debt -17.89 Cr16.60 Cr16.48 Cr13.95 Cr
Total Debt -75.24 Cr99.23 Cr147.79 Cr152.69 Cr
Total Equity -439.25 Cr491.25 Cr518.35 Cr530.28 Cr
Shares Outstanding -4.82 Cr4.82 Cr4.83 Cr4.83 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow -34.02 Cr43.26 Cr41.94 Cr66.75 Cr
Investing Cash Flow --12.65 Cr-43.55 Cr-56.43 Cr-64.60 Cr
Financing Cash Flow --19.84 Cr98.85 L25.87 Cr-20.94 Cr
Capital Expenditure --61.05 Cr-56.61 Cr-58.92 Cr-67.13 Cr
Free Cash Flow --27.02 Cr-13.36 Cr-16.98 Cr-37.44 L
Net Change in Cash -1.53 Cr69.46 L11.38 Cr-18.79 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % -31.8%31.8%35.7%35.6%
Operating Margin % -8.3%10.1%9.1%8.9%
Net Margin % -5.0%8.4%6.1%3.8%
ROE % -6.2%10.4%7.4%4.9%
ROCE % -9.6%11.7%10.3%10.7%

Shareholding Pattern

Insiders
48.88%
Institutions
0.19%
Public Float
0.37%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for KOPRAN

No recent headlines available.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space